MedTrace Logo

Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes

NCT07580638 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 3550

Last updated 2026-05-12

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the comprehensive clinical efficacy, cardiovascular, renal, and hepatic benefits, as well as the safety of adding Chiglitazar to SGLT-2 inhibitor therapy in adult patients with Type 2 Diabetes Mellitus (T2DM) . The main questions it aims to answer are:

What is the real-world effectiveness of Chiglitazar, when added to an SGLT-2 inhibitor, on glycemic control? What are the effects of this combination therapy on cardiovascular, renal, and hepatic outcomes? What is the overall safety of this treatment regimen?

This is a non-interventional study. Participants will be prescribed Chiglitazar or other oral antidiabetic drugs by their treating physician as part of their routine clinical care. For the purpose of this registry study, data will be collected from their regular medical follow-ups. Participants will:

Attend regular follow-up visits as part of their standard diabetes care. Have data collected from their routine clinical assessments.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

SGLT-2 inhibitor and Chiglitazar

Prescribed as an add-on therapy to an SGLT-2 inhibitor-based regimen according to the physician's clinical judgment and routine practice

DRUG

SGLT-2 inhibitor and Other Oral Antidiabetic Drugs (OADs)

Any oral antidiabetic drug (other than Chiglitazar) prescribed by the treating physician as an add-on therapy to an SGLT-2 inhibitor-based regimen.

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-18
Primary Completion
2028-01-18
Completion
2028-07-18

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07580638 on ClinicalTrials.gov